GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Thor Medical ASA (LTS:0R6Y) » Definitions » Cyclically Adjusted Price-to-FCF

Thor Medical ASA (LTS:0R6Y) Cyclically Adjusted Price-to-FCF : (As of May. 28, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Thor Medical ASA Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Thor Medical ASA Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Thor Medical ASA's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Thor Medical ASA Cyclically Adjusted Price-to-FCF Chart

Thor Medical ASA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Thor Medical ASA Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Jun23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Thor Medical ASA's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Thor Medical ASA's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Thor Medical ASA's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Thor Medical ASA's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Thor Medical ASA's Cyclically Adjusted Price-to-FCF falls into.



Thor Medical ASA Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Thor Medical ASA's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Thor Medical ASA's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0/131.9000*131.9000
=0.000

Current CPI (Dec. 2023) = 131.9000.

Thor Medical ASA Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201212 0.000 94.700 0.000
201306 0.000 95.700 0.000
201312 0.000 96.600 0.000
201403 -0.531 97.300 -0.720
201406 -0.687 97.500 -0.929
201409 -0.376 98.500 -0.503
201412 -0.802 98.600 -1.073
201503 -0.965 99.200 -1.283
201506 -0.874 100.100 -1.152
201509 -1.042 100.600 -1.366
201512 -0.826 100.900 -1.080
201603 -1.287 102.500 -1.656
201606 -1.106 103.800 -1.405
201609 -1.023 104.200 -1.295
201612 -1.074 104.400 -1.357
201703 -1.238 105.000 -1.555
201706 -1.195 105.800 -1.490
201709 -1.248 105.900 -1.554
201712 -1.339 106.100 -1.665
201803 -2.112 107.300 -2.596
201806 -1.468 108.500 -1.785
201809 -1.436 109.500 -1.730
201812 -1.544 109.800 -1.855
201903 -2.011 110.400 -2.403
201906 -1.863 110.600 -2.222
201909 -1.776 111.100 -2.109
201912 -1.511 111.300 -1.791
202003 -1.733 111.200 -2.056
202006 -1.835 112.100 -2.159
202009 -1.396 112.900 -1.631
202012 -0.825 112.900 -0.964
202103 -1.409 114.600 -1.622
202106 -1.057 115.300 -1.209
202109 -0.830 117.500 -0.932
202112 -0.941 118.900 -1.044
202203 -1.318 119.800 -1.451
202206 -0.676 122.600 -0.727
202212 0.000 125.900 0.000
202306 0.000 130.400 0.000
202312 0.000 131.900 0.000

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Thor Medical ASA  (LTS:0R6Y) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Thor Medical ASA Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Thor Medical ASA's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Thor Medical ASA (LTS:0R6Y) Business Description

Industry
Traded in Other Exchanges
Address
Kjelsasveien 168 B, Oslo, NOR, 0884
Nordic Nanovector ASA is a biopharmaceutical company. It is engaged in the development and commercialization of targeted therapeutics to improve the lives of patients with haematological cancers, such as non-Hodgkin lymphoma and leukaemia. The company's main clinical stage product is Betalutin.

Thor Medical ASA (LTS:0R6Y) Headlines

No Headlines